Rocket Pharmaceuticals, Inc. (RCKT) shareholders
Close on Nov 18, 2026Market cap $231.62MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roderick Wong, M.D Joint filing with RTW Investments, LP (17.40%) | 18,401,313 | 17.60% | 13D (active) amendment | Dec 12, 2024 |
| Wellington Management Company LLP Joint filing with Wellington Management Group LLP (13.40%), Wellington Group Holdings LLP (13.40%) and 1 more | 13,995,177 | 12.90% | 13G (passive) amendment | Dec 31, 2024 |
| Wellington Group Holdings LLP Joint filing with Wellington Management Group LLP (11.80%), Wellington Investment Advisors Holdings LLP (11.80%) and 1 more | 12,626,491 | 11.80% | 13G (passive) amendment | Mar 31, 2025 |
| Lee S. Ainslie III Joint filing with Maverick Capital, Ltd. (7.80%), Maverick Capital Management, LLC (7.80%) | 8,363,813 | 7.80% | 13G (passive) amendment | Jun 30, 2025 |
| Wellington Management Group LLP Joint filing with Wellington Group Holdings LLP (6.70%), Wellington Investment Advisors Holdings LLP (6.70%) and 1 more | 7,151,721 | 6.70% | 13G (passive) amendment | Apr 30, 2025 |
| BlackRock, Inc. | 5,930,178 | 6.60% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RCKT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Rtw Investments, LP | 17,687,772 | 16.11% | $60.49M | – | 0.52% |
| BlackRock, Inc. | 9,923,962 | 9.04% | $33.94M | +2,089,167 | 0.00% |
| Vanguard Portfolio Management LLC | 5,810,033 | 5.29% | $19.87M | +1,119,818 | 0.00% |
| Citigroup Inc | 4,865,551 | 4.43% | $16.64M | −242,157 | 0.01% |
| Marshall Wace, Llp | 4,029,262 | 3.67% | $13.78M | +990,547 | 0.01% |
| Millennium Management LLC | 4,000,344 | 3.64% | $13.68M | +882,220 | 0.00% |
| Newtyn Management, LLC | 4,000,000 | 3.64% | $13.68M | +834,100 | 1.71% |
| Maverick Capital Ltd | 3,923,963 | 3.57% | $13.42M | +356,591 | 0.12% |
| Vanguard Capital Management LLC | 3,784,387 | 3.45% | $12.94M | +8,651 | 0.00% |
| Aqr Capital Management LLC | 3,386,162 | 3.08% | $11.58M | +316,232 | 0.00% |
| Goldman Sachs Group Inc | 2,833,427 | 2.58% | $9.69M | +1,112,311 | 0.00% |
| Monaco Asset Management SAM | 2,480,468 | 2.26% | $8.48M | +422,165 | 0.67% |
| Geode Capital Management, LLC | 2,370,729 | 2.16% | $8.11M | +181,473 | 0.00% |
| Federated Hermes, Inc. | 2,304,207 | 2.10% | $7.88M | +1,280,460 | 0.01% |
| JPMorgan Chase & Co | 1,988,413 | 1.81% | $6.70M | +1,192,189 | 0.00% |
| Jacobs Levy Equity Management, Inc | 1,974,896 | 1.80% | $6.75M | +1,558,363 | 0.02% |
| State Street Corp | 1,820,121 | 1.66% | $6.22M | −2,665,868 | 0.00% |
| Dimensional Fund Advisors LP | 1,125,500 | 1.03% | $3.85M | +837,236 | 0.00% |
| Morgan Stanley | 1,062,522 | 0.97% | $3.63M | −957,586 | 0.00% |
| Opaleye Management Inc. | 1,000,000 | 0.91% | $3.42M | +45,000 | 0.31% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 180 | 100M | 90.9% | 18 / 72 | 65 / 33 | 18M | 15M |
| Q1 2026 | 199 | 97M | 88.5% | 48 / 80 | 53 / 32 | 31M | 17M |
| Q4 2025 | 186 | 91M | 83.2% | 31 / 61 | 71 / 18 | 14M | 21M |
| Q3 2025 | 173 | 99M | 89.9% | 28 / 60 | 63 / 50 | 16M | 13M |
| Q2 2025 | 196 | 95M | 87.0% | 41 / 80 | 48 / 80 | 27M | 39M |
| Q1 2025 | 236 | 108M | 98.2% | 49 / 112 | 41 / 35 | 12M | 14M |
| Q4 2024 | 225 | 110M | 99.9% | 59 / 97 | 44 / 25 | 26M | 10M |
| Q3 2024 | 192 | 93M | 85.0% | 34 / 66 | 53 / 19 | 14M | 7M |
| Q2 2024 | 178 | 92M | 84.0% | 21 / 75 | 50 / 27 | 6M | 9M |
| Q1 2024 | 185 | 94M | 86.0% | 19 / 69 | 62 / 27 | 9M | 4M |
| Q4 2023 | 194 | 90M | 82.3% | 37 / 69 | 64 / 17 | 8M | 7M |
| Q3 2023 | 175 | 89M | 81.4% | 29 / 79 | 45 / 17 | 17M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
159 funds held RCKT in Q2 2026, 43% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RCKT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,700,288 | 2.46% | $9.23M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,372,104 | 2.16% | $8.11M | 0.01% | Jun 30, 2026 |
| Vanguard Strategic Equity Fund | 1,696,761 | 1.55% | $5.80M | 0.05% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 1,037,971 | 0.95% | $3.23M | 0.14% | Jul 31, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 1,005,325 | 0.92% | $3.44M | 0.11% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,000,868 | 0.91% | $3.42M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 984,936 | 0.90% | $3.06M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 844,909 | 0.77% | $2.89M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 730,402 | 0.67% | $2.50M | 0.03% | Jun 30, 2026 |
| Bridge Builder Small/Mid Cap Growth Fund | 728,784 | 0.66% | $2.49M | 0.02% | Jun 30, 2026 |
| Vanguard Explorer Fund | 618,517 | 0.56% | $1.92M | 0.01% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 461,614 | 0.42% | $1.42M | 0.00% | May 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 459,902 | 0.42% | $1.57M | 0.03% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 435,483 | 0.40% | $1.34M | 0.01% | May 31, 2026 |
| Federated Hermes MDT Small Cap Growth Fund | 432,567 | 0.39% | $1.35M | 0.16% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Martin Wilson | General Counsel | 541,013 | 0.49% | Nov 17, 2026 |
| Gaurav Shah | CEO | 1,459,812 | 1.33% | Nov 17, 2026 |
| Sarbani Chaudhuri | See Remarks | 257,937 | 0.23% | Nov 12, 2026 |
| Christopher James Stevens | Chief Operating Officer | 505,784 | 0.46% | Aug 13, 2026 |
| Joseph Manhede | Principal Accounting Officer | 52,576 | 0.05% | Jul 8, 2026 |
| John Militello | See Remarks | 89,780 | 0.08% | May 28, 2026 |
| Syed Ali-aamir Rizvi | Chief Medical Officer | 407,874 | 0.37% | Feb 13, 2026 |
| Jonathan David Schwartz | See Remarks | 299,064 | 0.27% | Nov 20, 2025 |
| Aaron Ondrey | Chief Financial Officer | 128,173 | 0.12% | Jul 8, 2025 |
| Kinnari Patel | See Remarks | 573,628 | 0.52% | May 22, 2025 |
| David P. Southwell | Director | 317,646 | 0.29% | Aug 5, 2026 |
| Roderick Wong | Director, 10% owner | 18,263,956 | 16.64% | Jul 6, 2026 |
| Fady Ibraham Malik | Director | 52,862 | 0.05% | Jul 6, 2026 |
| Mikael Dolsten | Director | 67,082 | 0.06% | Jul 6, 2026 |
| Peter Fong | Director | 76,195 | 0.07% | Jul 6, 2026 |
| Carsten Boess | Director | 52,862 | 0.05% | Jul 6, 2026 |
| Elisabeth Bjork | Director | 50,000 | 0.05% | Jan 6, 2026 |
| Rtw Investments, Lp | Director, 10% owner | 18,295,124 | 16.67% | Sep 23, 2025 |
| Gotham Makker | Director | 1,017,412 | 0.93% | Jul 18, 2025 |
| Pedro P. Granadillo | Director | 54,734 | 0.05% | Jul 18, 2025 |
| Piratip Pratumsuwan | Director | 30,000 | 0.03% | Jul 18, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gaurav Shah CEO | Nov 13, 2026 | Sale | −3,020 | $2.25 | $6.80K | 1,053,574 |
| Martin Wilson General Counsel | Nov 13, 2026 | Sale | −4,087 | $2.25 | $9.20K | 541,013 |
| Sarbani Chaudhuri See Remarks | Nov 9, 2026 | Sale | −4,872 | $2.33 | $11.34K | 257,937 |
| Martin Wilson General Counsel | Nov 5, 2026 | Sale | −53,389 | $2.39 | $127.81K | 545,100 |
| Martin Wilson General Counsel | Sep 11, 2026 | Sale | −75,364 | $3.40 | $256.24K | 598,489 |
| Gaurav Shah CEO | Aug 18, 2026 | Sale | −2,293 | $3.38 | $7.75K | 1,056,594 |
| Martin Wilson General Counsel | Aug 18, 2026 | Sale | −631 | $3.38 | $2.13K | 673,853 |
| Martin Wilson General Counsel | Aug 13, 2026 | Sale | −3,493 | $3.38 | $11.81K | 674,484 |
| Gaurav Shah CEO | Aug 13, 2026 | Sale | −2,837 | $3.38 | $9.59K | 1,058,887 |
| Sarbani Chaudhuri See Remarks | Aug 11, 2026 | Sale | −4,701 | $3.50 | $16.45K | 262,809 |
| Christopher James Stevens Chief Operating Officer | Aug 11, 2026 | Sale | −36,658 | $3.50 | $128.30K | 505,784 |
| Christopher James Stevens Chief Operating Officer | Aug 3, 2026 | Award | +73,313 | – | – | 542,442 |
| David P. Southwell Director | Aug 3, 2026 | Other | +150,000 | – | – | 204,522 |
| Mikael Dolsten Director | Jun 18, 2026 | Award | +22,862 | – | – | 67,082 |
| Carsten Boess Director | Jun 18, 2026 | Award | +22,862 | – | – | 52,862 |
| David P. Southwell Director | Jun 18, 2026 | Award | +22,862 | – | – | 54,522 |
| Fady Ibraham Malik Director | Jun 18, 2026 | Award | +22,862 | – | – | 52,862 |
| Peter Fong Director | Jun 18, 2026 | Award | +22,862 | – | – | 76,195 |
| Roderick Wong Director, 10% owner | Jun 18, 2026 | Award | +27,832 | – | – | 75,499 |
| Gaurav Shah CEO | May 21, 2026 | Option exercise | +76,490 | $1.69 | $129.27K | 1,117,408 |
| Gaurav Shah CEO | May 21, 2026 | Sale | −55,684 | $3.09 | $172.06K | 1,061,724 |
| Gaurav Shah CEO | May 19, 2026 | Sale | −2,409 | $3.01 | $7.25K | 1,040,918 |
| Martin Wilson General Counsel | May 19, 2026 | Sale | −662 | $3.01 | $1.99K | 677,977 |
| John Militello See Remarks | May 19, 2026 | Sale | −384 | $3.01 | $1.16K | 89,780 |
| John Militello See Remarks | May 13, 2026 | Sale | −855 | $3.61 | $3.09K | 90,164 |
| Gaurav Shah CEO | May 13, 2026 | Sale | −2,728 | $3.61 | $9.85K | 1,043,327 |
| Martin Wilson General Counsel | May 13, 2026 | Sale | −3,361 | $3.61 | $12.13K | 678,639 |
| Sarbani Chaudhuri See Remarks | May 7, 2026 | Sale | −17,650 | $3.84 | $67.78K | 267,510 |
| Martin Wilson General Counsel | Feb 18, 2026 | Sale | −1,376 | $3.34 | $4.60K | 682,000 |
| John Militello See Remarks | Feb 18, 2026 | Sale | −1,157 | $3.34 | $3.86K | 91,019 |
| Gaurav Shah CEO | Feb 18, 2026 | Sale | −5,990 | $3.34 | $20.01K | 1,046,055 |
| Martin Wilson General Counsel | Feb 13, 2026 | Sale | −12,253 | $3.31 | $40.56K | 683,376 |
| John Militello See Remarks | Feb 13, 2026 | Sale | −3,726 | $3.31 | $12.33K | 92,176 |
| Gaurav Shah CEO | Feb 13, 2026 | Sale | −12,279 | $3.31 | $40.64K | 1,052,045 |
| Gaurav Shah CEO | Feb 11, 2026 | Award | +286,028 | – | – | 1,064,324 |
| Martin Wilson General Counsel | Feb 11, 2026 | Award | +311,813 | – | – | 695,629 |
| Syed Ali-aamir Rizvi Chief Medical Officer | Feb 11, 2026 | Award | +61,963 | – | – | 407,874 |
| Christopher James Stevens Chief Operating Officer | Feb 11, 2026 | Award | +61,963 | – | – | 469,129 |
| John Militello See Remarks | Feb 11, 2026 | Award | +29,982 | – | – | 95,902 |
| Sarbani Chaudhuri See Remarks | Feb 11, 2026 | Award | +125,924 | – | – | 285,160 |
| Elisabeth Bjork Director | Jan 2, 2026 | Buy | +10,000 | $3.44 | $34.40K | 50,000 |
| Jonathan David Schwartz See Remarks | Nov 18, 2025 | Sale | −2,545 | $2.98 | $7.58K | 299,064 |
| John Militello See Remarks | Nov 18, 2025 | Sale | −1,086 | $2.98 | $3.24K | 65,920 |
| Gaurav Shah CEO, Director | Nov 18, 2025 | Sale | −6,276 | $2.98 | $18.70K | 778,296 |
| Martin Wilson General Counsel | Nov 18, 2025 | Sale | −1,646 | $2.98 | $4.91K | 383,816 |
| Martin Wilson General Counsel | Nov 3, 2025 | Award | +100,000 | – | – | 385,462 |
| John Militello See Remarks | Oct 14, 2025 | Sale | −5,514 | $3.97 | $21.89K | 70,569 |
| John Militello See Remarks | Oct 14, 2025 | Sale | −3,005 | $3.97 | $11.93K | 67,564 |
| John Militello See Remarks | Oct 14, 2025 | Sale | −558 | $3.98 | $2.22K | 67,006 |
| John Militello See Remarks | Oct 14, 2025 | Sale | −19,841 | $3.96 | $78.57K | 76,083 |
| Syed Ali-aamir Rizvi Chief Medical Officer | Oct 6, 2025 | Award | +283,018 | – | – | 283,018 |
| Syed Ali-aamir Rizvi Chief Medical Officer | Oct 6, 2025 | Award | +62,893 | – | – | 345,911 |
| Peter Fong Director | Sep 24, 2025 | Award | +30,000 | – | – | 53,333 |
| Peter Fong Director | Sep 24, 2025 | Award | +23,333 | – | – | 23,333 |
| Rtw Investments, Lp Director, 10% owner | Sep 19, 2025 | Option exercise | +59,000 | $17.81 | $1.05M | 18,247,457 |
| Rtw Investments, Lp Director, 10% owner | Sep 19, 2025 | Other | −41,000 | $3.11 | $127.51K | 18,188,457 |
| Rtw Investments, Lp Director, 10% owner | Sep 19, 2025 | Option exercise | +41,000 | $19.09 | $782.69K | 18,229,457 |
| Rtw Investments, Lp Director, 10% owner | Sep 19, 2025 | Other | −1,000,000 | $3.11 | $3.11M | 18,188,457 |
| Rtw Investments, Lp Director, 10% owner | Sep 19, 2025 | Option exercise | +1,000,000 | $40.03 | $40.03M | 19,188,457 |
| Rtw Investments, Lp Director, 10% owner | Sep 19, 2025 | Other | −59,000 | $3.11 | $183.49K | 18,188,457 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Rocket Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 28,613 shares on Aug 31, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Christopher James Stevens Officer | Nov 9, 2026 | 16,131 | $37.53K | Nov 9, 2026 | Restricted Stock Vesting |
| Sarbani Chaudhuri Officer | Nov 9, 2026 | 4,872 | $11.34K | Nov 9, 2026 | Restricted Stock Vesting |
| Martin Wilson Officer | Nov 5, 2026 | 53,389 | $127.81K | Nov 5, 2026 | Restricted Stock Vesting |
| John Militello Former Officer | Sep 15, 2026 | 6,897 | $22.73K | Sep 15, 2026 | Restricted Stock Vesting |
| John Militello Former Officer | Sep 14, 2026 | 6,857 | $22.73K | Sep 14, 2026 | Restricted Stock Vesting |
| Martin Wilson Officer | Sep 11, 2026 | 75,364 | $256.49K | Sep 11, 2026 | Restricted Stock Vesting |
| John Militello Former Officer | Sep 11, 2026 | 8,923 | $30.37K | Sep 11, 2026 | Restricted Stock Vesting |
| John Militello Former Officer | Aug 18, 2026 | 1,252 | $4.23K | Aug 18, 2026 | Restricted Stock Vesting |
| Martin Wilson Officer | Aug 18, 2026 | 631 | $2.13K | Aug 18, 2026 | Restricted Stock Vesting |
| Gaurav Shah Officer, Director | Aug 18, 2026 | 2,293 | $7.75K | Aug 18, 2026 | Restricted Stock Vesting |
| Martin Wilson Officer | Aug 13, 2026 | 3,493 | $11.81K | Aug 13, 2026 | Restricted Stock Vesting |
| Gaurav Shah Officer, Director | Aug 13, 2026 | 2,837 | $9.59K | Aug 13, 2026 | Restricted Stock Vesting |
| Sarbani Chaudhuri Officer | Aug 11, 2026 | 4,701 | $16.45K | Aug 11, 2026 | Restricted Stock Vesting |
| Christopher James Stevens Officer | Aug 11, 2026 | 36,658 | $128.28K | Aug 11, 2026 | Restricted Stock Vesting |
| Fady Ibraham Malik Director | Jul 7, 2026 | 10,670 | $41.39K | Jul 7, 2026 | Restricted Stock Vesting |
See a number that looks wrong?